EUVIMEDEUVIMED entdecken
Crossref

L26/P-146 Melatonin supplementation during in vitro maturation restores oocyte quality and developmental competence in aged mice

H. Park, K. Juhn, E. Jung, J. Jin, Y. Kang, J. Lim, J. Yoon

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von H. Park und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Can melatonin supplementation during in vitro maturation (IVM) improve oocyte quality and developmental potential in aged mice? Summary answer Melatonin supplementation improved mitochondrial homeostasis, reduced ROS-induced DNA damage, and enhanced protein synthesis and DNA methylation, leading to improved blastocyst quality and outgrowth capacity. What is known already Advanced maternal age is associated with increased oxidative stress within the follicular microenvironment. Human studies have demonstrated elevated lipid peroxidation and impaired antioxidant defense in follicular fluid from women aged ≥37 years, indicating excessive ROS that compromise oocyte quality. Oocyte aging is associated with mitochondrial dysfunction and ROS accumulation, which can induce DNA double-strand breaks. Oocytes from aged mice also exhibit epigenetic dysregulation that impairs early embryonic development. Collectively, these findings indicate that oxidative stress is a key contributor to age-related oocyte dysfunction. We therefore investigated whether melatonin supplementation during IVM could restore oocyte quality under aging-associated oxidative conditions. Study design, size, duration This study was conducted using germinal vesicle (GV) stage oocytes collected from aged (70–90 weeks) mice. Following in vitro maturation with or without melatonin supplementation (5 μM), oocytes were subjected to parthenogenetic activation. Developmental competence was evaluated from cleavage (2-cell stage) through blastocyst formation on Day 4 and subsequent in vitro outgrowth expansion. Experiments were performed across multiple independent biological replicates. Participants/materials, setting, methods Mitochondrial membrane potential was assessed using JC-1 staining. Intracellular ROS levels and DNA damage were quantified using DCFH-DA and γ-H2AX immunostaining, respectively. Global DNA methylation (5mC) and nascent protein synthesis (HPG incorporation) were also evaluated using immunofluorescence intensity. Developmental competence was assessed by 2-cell cleavage rate and blastocyst formation. Blastocyst quality was evaluated based on total cell number and ICM:TE ratio using differential staining. Implantation potential was assessed using a fibronectin-coated in vitro outgrowth assay. Main results and the role of chance Following in vitro maturation with melatonin supplementation, mitochondrial membrane potential was significantly restored (P < 0.05) and intracellular ROS levels were markedly reduced in oocytes from aged mice (P < 0.0001), leading to a significant decrease in γ-H2AX–positive DNA damage foci (P < 0.01). Melatonin-treated oocytes from aged mice also exhibited recovered global protein synthesis and restored global DNA methylation (5mC) levels (P < 0.05). Importantly, developmental competence after parthenogenetic activation was significantly improved, as reflected by increased 2-cell formation rates following IVM with melatonin (61.2% vs. 45.8% in aged controls, P < 0.05). These molecular and cellular improvements contributed to enhanced developmental outcomes, with a 56.9% increase in usable embryo yield, defined as the proportion of GV-stage oocytes that successfully developed to the blastocyst stage, compared with aged controls (50.2% vs. 32.0%, P < 0.05). Blastocysts from oocytes matured in the presence of melatonin exhibited higher total cell numbers (115.4 vs. 98.6, P < 0.05) and improved ICM:TE ratios (0.35 vs. 0.31). Furthermore, outgrowth assays demonstrated significantly expanded areas for both ICM and TE (P < 0.05), confirming enhanced implantation potential. Limitations, reasons for caution Developmental competence was assessed using parthenogenetic activation. Further studies using IVF and embryo transfer are required to confirm live birth outcomes and to evaluate the effects of melatonin on paternal chromatin and syngamy. Wider implications of the findings Melatonin was associated with improved mitochondrial function and partial restoration of translational and epigenetic stability in oocytes from aged mice. These findings suggest that melatonin supplementation during IVM may be a potential approach to enhance oocyte quality and contribute to better ART outcomes in patients of advanced maternal age. Trial registration number No

Zitieren

APA

Park, H., Juhn, K., Jung, E., Jin, J., Kang, Y., Lim, J., & Yoon, J. (2026). L26/P-146 Melatonin supplementation during in vitro maturation restores oocyte quality and developmental competence in aged mice. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.482

Vancouver

Park H, Juhn K, Jung E, Jin J, Kang Y, Lim J, et al. L26/P-146 Melatonin supplementation during in vitro maturation restores oocyte quality and developmental competence in aged mice. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.482

BibTeX
@article{Park2026,
  author = {Park, H. and Juhn, K. and Jung, E. and Jin, J. and Kang, Y. and Lim, J. and Yoon, J.},
  title = {L26/P-146 Melatonin supplementation during in vitro maturation restores oocyte quality and developmental competence in aged mice},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.482}
}
Kostenlos starten →